Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, OncoTherapy Science's enterprise value is 円6,246.9 Mil.
OncoTherapy Science's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円-881.7 Mil. Therefore, OncoTherapy Science's EV-to-EBITDA for today is -7.08.
The historical rank and industry rank for OncoTherapy Science's EV-to-EBITDA or its related term are showing as below:
TSE:4564'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.43 Med: -6.3 Max: -1.72
Current: -7.08
During the past 13 years, the highest EV-to-EBITDA of OncoTherapy Science was -1.72. The lowest was -17.43. And the median was -6.30.
TSE:4564's EV-to-EBITDA is ranked worse than 100% of 413
companies
in the Biotechnology industry
Industry Median: 13.87
vs TSE:4564: -7.08
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
OncoTherapy Science's PE Ratio (TTM) for today is calculated as:
OncoTherapy Science's share price for today is 円21.00.
OncoTherapy Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-2.360.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for OncoTherapy Science's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4564 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, OncoTherapy Science's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoTherapy Science EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoTherapy Science's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where OncoTherapy Science's EV-to-EBITDA falls into.
OncoTherapy Science's current Enterprise Value is 円6,246.9 Mil.
OncoTherapy Science's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-881.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoTherapy Science (TSE:4564) has a EV-to-EBITDA of -7.08 as of Aug. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on OncoTherapy Science. According to the industry distribution chart, OncoTherapy Science ranks #999999 out of 413 companies in the Biotechnology industry.
Is OncoTherapy Science's EV-to-EBITDA too high?
OncoTherapy Science's current EV-to-EBITDA is -7.08. Based on the distribution chart, OncoTherapy Science ranks #999999 out of 413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoTherapy Science ranks #999999 out of 413 companies for EV-to-EBITDA. This places OncoTherapy Science in the lower half of its industry. The industry median EV-to-EBITDA is 13.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.87, based on 413 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on OncoTherapy Science. For the Biotechnology industry, the median EV-to-EBITDA is 13.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoTherapy Science's current EV-to-EBITDA is -7.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円18.16, compared to a current price of 円21.00 — trading 15.6% above its estimated fair value. The current EV-to-EBITDA is -7.08. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current EV-to-EBITDA is -7.08 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (TSE:4564) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of 円21.00 is trading 15.6% above its estimated GF Value™ of 円18.16.
GuruFocus considers OncoTherapy Science to be Modestly Overvalued.
Key valuation signals for TSE:4564:
EV-to-EBITDA: -7.08
GF Value™: 円18.16 vs. price of 円21.00 (15.6% above fair value)
No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score
Get the complete analysis for TSE:4564
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4564 has been successfully added to your 
